ISTC (International Science&Technology Center)

 ISTC is an intergovernmental organization established in 1992 by agreement between the European Union, Japan, Russian Federation, and United States of America.

Since this time, Armenia, Belarus, Georgia, Kazakstan and the Kyrgyz Republic joined the ISTC. Norway acceded in 1997, the Republic of Korea in May 1998 and Tajikistan in March 2003.

ISTC Projects (Georgia : Eliava institute)

Click on the number for details :
 
A-2140: Phage therapy against MDR Salmonella infections, G-1021: Transmission of Water-Borne Infections, G-1028: Bacteriophages Against Intestinal Infections, G-1037: Bacteriophages for Treatment Cow Metritis and Endometritis, G-1064: Properties of Phages for Production of Preparation, G-1242: Purulent Infections of Neonates and Prevention with Bacteriophages, G-1369: Bacteriophages against Chronic Prostatitis Microflora, G-1556: Vaccine based on Phage Lysis Products, G-1666: Bacteriophage Composite against Dental Infections, G-1735: Interaction between Bacteriophages and Antibiotics, G-2055: Phage-probiotic, G-416: Anti-Anthrax Immunoglobulin, G-416.2: Anti-Anthrax Immunoglobulin, G-416.3: Anti-Anthrax Immunoglobulin, G-510: Bacteriophages Against Infectious Diseases, G-587: Genomic and Biochemical Analysis of Bacteriophage Infection, G-589: Controlled-Release Drugs with Bacteriophages, G-591: Tuberculosis Bacteriophage, G-595: Killer Proteins, G-824: Bacteriophages in Different Medicinal Forms

Globalyz Biotech

 Web site

Comment:
like a georgian company with the same menu :

• Skin and soft tissue infections associated with burns, wounds, bites from humans, animals, or insects, cellulitis, abscesses, folliculitis, impetigo and pyoderma
• Bone and joint infections such as bacterial arthritis and osteomyelitis
• Eye infections such as bacterial conjunctivitis
• Urinary tract infections associated with prostatitis, urethritis and cystitis
• Ear, Nose, Throat infections associated with sinusitis, pharyngitis, otitis media, and otitis externa
• Respiratory infections associated with cystic fibrosis and chronic respiratory diseases
• Infections of oral cavity, such as gingivitis and stomatitis
• Gastrointestinal conditions such as bacterial gastroenteritis and bacterial overgrowth syndrome

Therapeutic phages are available to treat several bacterial species including but not limited to the following:

• Staphylococcus spp.
• Streptococcus spp.
• E. coli spp.
• Proteus spp.
• Pseudomonas spp.
• Shigella spp.
• Salmonella spp.
• Enterococcus spp.
• Klebsiella spp.

NovoMed Integrative Medicine Center (Georgia)

List of Bacteria where is applied Phage therapy:

Staphylococcus spp. Enterococcus spp. Pseudomonas aeruginosa Proteus mirabilis, Proteus vulgaris Streptococcus spp. Escherichia coli Salmonella spp. Shigella spp. Klebsiella spp. Click  on each heading

What are the success rates for phage therapy?

Results of bacteriophage treatment (1307 cases)

What infections / conditions are not treatable with phage therapy?
There are a number of pathogens for which there are currently no therapeutic phage preparations available; the list includes:

• Mycobacterium (all species, including tuberculosis)
• Clostridium difficile
• Citrobacter
• Borrelia burgdorferi (Lyme Disease)

In many cases, however, NovoMed Integrative Medicine Center uses other similarly unique, safe and approved medical alternatives to treat many of the above species. If you have questions about what pathogens or medical conditions can be treated by NovoMed Integrative Medicine Center, please send an inquiry to office@imcgeorgia.com.

Phagobioderm

Now we all write about Phage therapy but where are the results?

The main target where there is a good chance of success for  phage therapy  is the skin  infection because  in this situation  there are few  adverse factors.


From

 

 The reasons are:
-easy medication
-easy check
- use of one Lytic Phage  or Phage cocktail
-direct contact with bacteria
-no antibodies
- easy to remove phage by washing
-et cetera


  In my old web site there is this document  from :

 
that now is unobtainable.

Comment:

 First we must   test  phage therapy in this  clinical area (and after in the others)

We must consolidate the theory but also to put it into the practice

It is  unsatisfactory to write  on Phage therapy only for publications

Why the PhagoBurn project is started ?   For the same reasons described above .

Pseudomonas aeruginosa: an expert opinion from Russia

 Here

Close study of the poster "Pathogen eradication by phage therapy in patients wich chronic bacterial prostatitis"

Unfortunately for the moment the clinical cases  where  Phage therapy  is applied are infrequent.
For learning  it is inevitable to read the experience of others.

I start with a close study of this poster:

1-Disease (here):

 2-Methods:

-22 men with CBP and positive bacterial culture of expressed prostatic fluid (EPS)
- bacteria:
E.fecalis: n=16
E.coli: n=5
K.pneumoniae: n=2
P.aeruginosa: n=1
S.haemoliticus: n=1
-No presence of other micro-organisms (Chlamidia, Mycoplasma etc.)*
-No any drugs for at least one month
-measurement of the prostate size and of the urinary flow rate
- measurement of the index NIH-CPSI
-statistical  valuation

3-Phage treatment (year 2013):

 Comment:

Phage preparation is the same from:

here  ( year 1981)

 (

Phage preparation:

Phage preparation is the same from:


here ( year 2000)

Phage preparation:

 4-Results:

 

Mean PT duration: 47 days 
Eradication in 50% of the cases
No side effects

  almost too easy!!